Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia.
about
Long-acting injectable versus daily oral antipsychotic treatment trials in schizophrenia: pragmatic versus explanatory study designsPost-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases.Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism.Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injectionDose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia.Long-acting atypical antipsychotics: characterization of the local tissue responseEfficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data.Pharmacokinetics of olanzapine long-acting injection: the clinical perspective.Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects.Schizophrenia symptoms and functioning in patients receiving long-term treatment with olanzapine long-acting injection formulation: a pooled analysisAn evaluation of the use of olanzapine pamoate depot injection in seriously violent men with schizophrenia in a UK high-security hospital.The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.A Prospective Study Comparing the Long-term Effectiveness of Injectable Risperidone Long-acting Therapy and Oral Aripiprazole in Patients with SchizophreniaA randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation.Attitudes towards the administration of long-acting antipsychotics: a survey of physicians and nursesAntipsychotic drugs and obesity.Almost all antipsychotics result in weight gain: a meta-analysis.Adverse effects associated with second-generation antipsychotic long-acting injection treatment: a comprehensive systematic review.Predictors of psychiatric hospitalization during 6 months of maintenance treatment with olanzapine long-acting injection: post hoc analysis of a randomized, double-blind studyWithin-drug benefit-risk evaluation of olanzapine long-acting injection at one and two years of treatmentAre the long-acting intramuscular formulations of risperidone or paliperidone palmitate associated with post-injection delirium/sedation syndrome? An assessment of safety databases.Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database.Olanzapine long-acting injection: a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice.A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendationBaseline characteristics and hospitalizations in patients with schizophrenia receiving olanzapine long-acting injection: an interim analysis from a non-interventional, prospective observational safety studyTreatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons.Efficacy, tolerability, and safety of aripiprazole once-monthly versus other long-acting injectable antipsychotic therapies in the maintenance treatment of schizophrenia: a mixed treatment comparison of double-blind randomized clinical trialsThe Potential Role of Long-acting Injectable Antipsychotics in People with Schizophrenia and Comorbid Substance Use.Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece.Association between adherence to and persistence with atypical antipsychotics and psychiatric relapse among US Medicaid-enrolled patients with schizophrenia.Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.Postinjection Delirium/Sedation Syndrome with Olanzapine Depot Injection.Evaluation of olanzapine pamoate depot in seriously violent males with schizophrenia in the community.Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial.Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials.A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection.Olanzapine pamoate for the treatment of schizophrenia.A review of olanzapine pamoate.Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review.
P2860
Q28085407-87E49248-5F66-45A4-8823-900C3401FBA5Q33600247-56A61E90-97ED-4D71-AECA-210654D6C2BFQ33600259-1DC0048B-87CC-4F76-9E08-B5087AD61525Q33817737-67FC14B1-A516-4B23-A506-68172235D794Q33821379-A5F7BB36-E2C9-4CCE-AFB0-03B1560BC060Q34130433-956AD667-7EE9-4DC2-85E5-D9843F5CB4EDQ34286350-0A33BD28-B33D-49BC-B83A-FFC21AA1C123Q34293855-BCE63096-96DC-4959-8C07-2E60DEE446B8Q34293899-349C4B38-8339-4898-AF2F-401B704E2C34Q34315836-CF160BB4-FF3D-41D8-A43E-7A55262C6711Q34398243-1D11C814-D057-4C04-BF3C-6A104CD6C175Q34418833-AB942B12-0E29-4455-B317-8090C4101617Q34418847-27982B5C-BF5A-4144-9E4C-9A7274B9E07FQ34444162-F15BB399-99DE-4ABF-AA89-1F7E41ED840DQ34546038-903C8475-C1B7-4E05-BDD4-8FFAC4AC8B0FQ34588656-AB5B152C-C0F7-4A96-BEDC-EEF4E5053E8FQ34648940-FC696D1B-5C21-402B-9624-F69AF9E4FB7DQ34661499-CC1C1592-47DF-4F40-81BD-E4F49FCCB23AQ34775426-C8C0ED98-6F2B-45E2-B1BF-26873669C1F2Q34990923-0ABC2B37-373A-4559-AC83-8F88A8297014Q35030155-BC60B587-DCBA-460F-8DEE-F2229E279841Q35229068-CC5BEC6C-DC52-4857-AF7A-2A25A06AF050Q35249595-237C6F70-59C3-4703-B086-BAA1EE2EB581Q35321641-624B31D9-2027-4146-A913-710AD25164ECQ35683860-9CDFE49D-CDFE-467D-BA41-E9564349E46CQ35841195-0F248E74-B075-4E9C-A182-6F984CCD01FFQ35971060-F682DB0C-C56B-4A2D-8286-EBA0DB94D29EQ36001512-4CD6197B-E0A5-46F5-8FD1-F8200926F856Q36059843-B28BECC4-E145-4A86-8D5E-55F82B7C8130Q36198389-FE7F20EE-AD91-4D21-BAF9-2A4822942354Q36670942-FA891BD2-241D-4243-B2D5-7242120C9216Q36698856-99E0A1EA-8F56-404B-895B-CB7180F08C3FQ37167256-049BCF00-C5BF-4B9C-ABA7-BDA06BF60D03Q37282220-24C478FD-ED3B-4F51-A742-DA00658D70ADQ37341552-79B86777-1736-435D-855F-50606691AF05Q37451403-B576EF0F-FE0B-402D-911F-92E2825629EDQ37501165-E6490A0A-ED91-4F7F-9FA3-EE0F02106170Q37831310-6ABCF5C3-0072-40CB-9A65-54A545957A90Q38022638-04B35BA9-D346-4AD6-B4AA-4B80FD8E8BC5Q38042430-5FBC5C60-BC0E-47AC-BBB6-BD10E6C0903A
P2860
Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Olanzapine long-acting injecti ...... n patients with schizophrenia.
@en
Olanzapine long-acting injecti ...... n patients with schizophrenia.
@nl
type
label
Olanzapine long-acting injecti ...... n patients with schizophrenia.
@en
Olanzapine long-acting injecti ...... n patients with schizophrenia.
@nl
prefLabel
Olanzapine long-acting injecti ...... n patients with schizophrenia.
@en
Olanzapine long-acting injecti ...... n patients with schizophrenia.
@nl
P2093
P1476
Olanzapine long-acting injecti ...... n patients with schizophrenia.
@en
P2093
Daniel Y Lin
David McDonnell
Dieter Naber
Gopalan Sethuraman
Holland C Detke
Richard F Bergstrom
P304
P356
10.1176/APPI.AJP.2009.07081221
P407
P50
P577
2009-12-15T00:00:00Z